BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Osmotica Pharmaceutical and Upstate Pharma, LLC, a Subsidiary of UCB, Inc. (UCBJF.PK), Announce the Availability of Venlafaxine Extended-Release Tablets


10/9/2008 11:08:15 AM

WILMINGTON, N.C.--(BUSINESS WIRE)--Osmotica Pharmaceutical Corp. is announcing that Venlafaxine Extended-Release Tablets, 37.5 mg, 75 mg, 150 mg, and 225 mg, which was approved by the U.S. Food and Drug Administration in May, is now commercially available through its marketing partner, Upstate Pharma, LLC, a subsidiary of UCB, Inc. Shipments of the product to wholesalers and other commercial outlets began September 30, 2008 and promotion of the product will commence later in the month. Forrest Waldon, CEO of Osmotica Pharmaceutical stated, “We are excited about the launch of this innovative product and look forward to a successful commercial relationship.”

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->